1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 剤形別スニペット
3.2. 年齢層別スニペット
3.3. 用途別スニペット
3.4. 流通チャネル別スニペット
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. アレルギー疾患の増加
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 薬剤に関連する副作用と副反応
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 剤形別
6.1. はじめに
6.1.1. 剤形別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数：剤形別
6.2. 錠剤
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. ソリューション
6.4. シロップ
7. 年齢層別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, 年齢層別
7.1.2. 市場魅力度指数（年齢層別
7.2. 年齢層別
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 成人
7.4. 小児
8. 用途別
8.1. 導入
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数、用途別
8.2. アレルギー性鼻炎
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. アレルギー性結膜炎
8.4. 慢性蕁麻疹
8.5. 湿疹
8.6. その他
9. 販売チャネル別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.1.2. 市場魅力度指数（流通チャネル別
9.2. 病院薬局
9.2.1. はじめに
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 小売薬局
9.4. オンライン薬局
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（%）、剤形別
10.2.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.2.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.2.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.2.7. 市場規模分析および前年比成長率分析（%）, 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析（%）、剤形別
10.3.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.3.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.3.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.3.7. 市場規模分析および前年比成長率分析（%）, 国別
10.3.7.1. ドイツ
10.3.7.2. イギリス
10.3.7.3. フランス
10.3.7.4. スペイン
10.3.7.5. イタリア
10.3.7.6. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 剤形別市場規模分析および前年比成長率分析（%） 10.4.4.
10.4.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.4.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.4.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.4.7. 市場規模分析および前年比成長率分析（%）, 国別
10.4.7.1. ブラジル
10.4.7.2. アルゼンチン
10.4.7.3. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 剤形別市場規模分析および前年比成長率分析（%） 10.5.4.
10.5.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.5.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.5.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.5.7. 市場規模分析および前年比成長率分析（%）, 国別
10.5.7.1. 中国
10.5.7.2. インド
10.5.7.3. 日本
10.5.7.4. 韓国
10.5.7.5. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 剤形別市場規模分析および前年比成長率分析（%） 10.6.4.
10.6.4. 市場規模分析および前年比成長率分析（%）：年齢層別
10.6.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.6.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11. 競争環境
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Johnson & Johnson Services, Inc.*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. GSK plc
12.3. UCB S.A.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer Inc.
12.6. Major Pharmaceuticals
12.7. Cipla
12.8. Dr. Reddys Laboratories Ltd.
12.9. AdvaCare Pharma
12.10. Aden Healthcare (*リストは除く)
13. 付録
13.1. アデンについて
13.2. お問い合わせ

Report Overview
The Global Cetirizine Hydrochloride Market reached US$ 6,797.9 million in 2023 and is expected to reach US$ 8,882.5 million by 2031 growing with a CAGR of 3.4% during the forecast period 2024-2031.

Cetirizine hydrochloride is a second-generation antihistamine that works by selectively blocking the action of histamine, a chemical released by the body during an allergic reaction. Histamine binds to H1 receptors on target cells, triggering a cascade of events that leads to the typical symptoms of allergies such as sneezing, itchy and watery eyes, runny nose, and hives.
By binding to the H1 receptors, cetirizine prevents histamine from exerting its effects, thereby alleviating allergy symptoms. Compared to first-generation antihistamines, cetirizine has a higher affinity for the H1 receptor and is less likely to cross the blood-brain barrier, resulting in fewer central nervous system side effects like drowsiness.
The broad applicability of cetirizine for various allergic conditions, along with its favorable safety profile, has made it a widely preferred option among healthcare providers for patients spanning all age groups, from young children to the elderly.

Market Dynamics: Drivers
Increasing prevalence of allergic diseases
The demand for the global cetirizine hydrochloride market is driven by multiple factors. One of the key factors is the increasing prevalence of allergic diseases. The rise in allergic conditions, such as allergic rhinitis, eczema, and allergic conjunctivitis, is a primary driver for the cetirizine market.
Currently, over 150 million Europeans suffer from chronic allergic diseases. This number is expected to rise, with predictions indicating that by 2025, more than 50% of the EU population could be affected by allergies, including conditions like allergic rhinitis, asthma, and eczema. There is a growing awareness among the public regarding allergies and the available treatment options, which is leading to an increased demand for cetirizine. As more individuals become familiar with the symptoms of allergies, they are more inclined to seek effective medications to alleviate their discomfort.
Moreover, key players in the industry more focus on research & development, and a rising number of clinical trials are helping to propel this market growth. For instance, in January 2024, UCB announced the randomized Phase III Study aims to assess the efficacy and safety of Xyzal (levocetirizine) compared to Zyrtec (cetirizine) in subjects suffering from dermatitis. This type of study is crucial in clinical research as it provides robust data on how well these medications perform in treating dermatitis, which is often characterized by inflammation, redness, and itching of the skin.

Restraints
Factors such as side effects & adverse reactions associated with the drugs, and stringent regulatory requirements, are expected to hamper the market.

Market Segment Analysis
The global cetirizine hydrochloride market is segmented based on dosage form, age group, application, distribution channels, and region.
The tablets segment accounted for approximately 64.3% of the global cetirizine hydrochloride market share
The tablets segment is expected to hold the largest market share over the forecast period. Cetirizine hydrochloride tablets are essential in the global market as a reliable treatment for various allergic conditions, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis. The increasing prevalence of allergies and growing awareness of effective allergy management strategies are anticipated to sustain the demand for cetirizine tablets over the forecast period.
In addition, key players in the industry strategies such as partnerships and collaborations are helping to propel this market growth. For instance, in August 2023, the National Medical Products Administration (NMPA) granted Xinhua Pharmaceutical (Gaomi) Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical, the Approval Letter of Supplementary Application for Cetirizine Hydrochloride Tablets. This approval signifies that the product has successfully passed the quality and efficacy consistency evaluation required for generic drugs.

Market Geographical Share
North America accounted for approximately 43.9% of the global cetirizine hydrochloride market share
North America region is expected to hold the largest market share over the forecast period owing to the rise in allergic disorders, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis, which is a major factor propelling the demand for cetirizine hydrochloride in this region.
Allergic rhinitis, commonly known as hay fever, is a prevalent condition that affects a significant portion of the global population, with prevalence estimates ranging from 10% to 30%. In the United States, a substantial percentage of adults and children have reported experiencing seasonal allergies in recent years. According to data from the CDC, approximately 25.7% of U.S. adults and 18.9% of children stated they suffered from seasonal allergies in 2021.
This high prevalence of allergic rhinitis in the U.S. population creates a significant demand for antihistamine medications like cetirizine, which are effective in alleviating common symptoms associated with this condition, such as sneezing, runny nose, and itchy eyes. Moreover, growing public awareness of allergies and the treatment options accessible has led to a heightened demand for cetirizine.
Additionally, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and mergers & acquisitions are helping to propel this market growth in the region. For instance, in June 2022, Glenmark Pharmaceuticals Inc., USA, a fully owned subsidiary of Glenmark Pharmaceuticals Ltd., acquired the approved Abbreviated New Drug Applications (ANDAs) for several over-the-counter (OTC) drugs from Wockhardt Limited in the United States.
The acquired ANDAs include famotidine tablets USP, 10 mg and 20 mg (OTC) - used to treat and prevent ulcers in the stomach and intestine, cetirizine hydrochloride Tablets USP, 5 mg and 10 mg (OTC) - an antihistamine medication, and olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC) - indicated for allergic conjunctivitis and allergic rhinitis.

Market Segmentation
By Dosage Form
Tablets
Solutions
Syrups
By Age Group
Adult
Pediatric
By Applications
Allergic Rhinitis
Allergic Conjunctivitis
Chronic Urticaria
Eczema
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market

Competitive Landscape
The major global players in the cetirizine hydrochloride market include Johnson & Johnson Services, Inc., GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Major Pharmaceuticals, Cipla, Dr. Reddys Laboratories Ltd., AdvaCare Pharma, and Aden Healthcare among others.

Key Developments
In April 2023, Nicox SA announced that its exclusive partner in China, Ocumension Therapeutics, has submitted a New Drug Application (NDA) to obtain approval for the commercialization of Zerviate (cetirizine ophthalmic solution) at a concentration of 0.24%. This application is specifically for treating ocular itching associated with allergic conjunctivitis.

Why Purchase the Report?
To visualize the global cetirizine hydrochloride
Market Segmentation based on dosage form, age group, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the cetirizine hydrochloride market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global cetirizine hydrochloride market report would provide approximately 70 tables, 63 figures, and 183 pages.

Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Dosage Form
3.2. Snippet by Age Group
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Allergic Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side Effects and Adverse Reactions Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Dosage Form
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
6.1.2. Market Attractiveness Index, By Dosage Form
6.2. Tablet *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Solutions
6.4. Syrups
7. By Age Group
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Age Group*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adult
7.4. Pediatric
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Allergic Rhinitis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Allergic Conjunctivitis
8.4. Chronic Urticaria
8.5. Eczema
8.6. Others
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Johnson & Johnson Services, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GSK plc
12.3. UCB S.A.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer Inc.
12.6. Major Pharmaceuticals
12.7. Cipla
12.8. Dr. Reddys Laboratories Ltd.
12.9. AdvaCare Pharma
12.10. Aden Healthcare (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

※参考情報 セチリジン塩酸塩は、抗ヒスタミン薬の一種であり、主にアレルギー症状の緩和に使用されます。特に、季節性アレルギー性鼻炎や慢性蕁麻疹などの治療に効果的です。ヒスタミンは、体内でアレルギー反応を引き起こす物質であり、セチリジンはこのヒスタミンの作用を抑制することで、症状を軽減します。 セチリジンの化学的性質としては、ヒドロキシジンの誘導体であり、その構造により、特にH1受容体に対して選択的に作用します。これにより、他のタイプの受容体に対する副作用を最小限に抑えることができ、比較的眠気を引き起こしにくい特徴があります。これは、第二世代の抗ヒスタミン薬に分類される理由でもあります。一般的に、第一世代の抗ヒスタミン薬は眠気を引き起こしやすく、日常生活に支障をきたすことがありますが、セチリジンはそのリスクが低いため、多くの患者にとって使いやすい薬剤です。 セチリジン塩酸塩は、経口投与が行われ、通常は錠剤やシロップの形で処方されます。成人では、通常1日1回の服用が一般的ですが、重症度や医師の指示に応じて適宜調整されることがあります。小児にも使用されることがあり、年齢に応じた用量が定められています。特に、子どもに対しては、体重や年齢に基づいた適切な用量を守ることが重要です。 セチリジンは、その用途の広さから、さまざまなアレルギー症状の緩和に貢献しています。典型的には、くしゃみ、鼻水、鼻づまり、目のかゆみや涙などが含まれます。また、季節性アレルギーに加えて、動物の毛やダニ、カビなどによるアレルギー反応にも効果があります。これにより、アレルギー性反応による生活の質の低下を防ぎ、患者の快適な生活をサポートします。 さらに、セチリジンは、その抗ヒスタミン作用のほか、抗炎症作用も示すことがあるため、気道の炎症を軽減するための補助療法としても利用されることがあります。ただし、慢性的なアレルギー症状の場合は、セチリジン単独では十分な効果が得られないこともあるため、他の治療法との併用が考慮されることが一般的です。 近年、セチリジンの利用方法は多様化しています。例えば、アレルギーの症状を予防的に管理するために、シーズン前からの服用が推奨されることもあります。これにより、急激な症状の発生を防ぐことができ、患者の生活の質を向上させる手助けとなります。医療現場では、アレルギーの種類や患者のライフスタイルに応じて、個別化された治療計画が立てられることが重要とされています。 また、セチリジンの副作用についても認識しておくことが大切です。一般的には、副作用として軽度の眠気や口渇が報告されますが、これらは個人によって異なる反応を引き起こすことがあります。服用中に異常を感じた場合は、速やかに医師に相談することが推奨されます。特に運転や危険な作業を行う人にとっては、注意が必要です。 現在の研究では、セチリジンを含む抗ヒスタミン剤の新たな利用法や、他の薬剤との併用による相乗効果の検討が進められています。新しい形態の製剤や、より効率的な投与方法の開発も行われており、患者にとってより利用しやすい治療法が追求されています。以上のように、セチリジン塩酸塩は、アレルギー治療において重要な役割を果たす薬剤であり、今後もその研究と応用が期待されています。

*** セチリジン塩酸塩の世界市場に関するよくある質問(FAQ) ***

・セチリジン塩酸塩の世界市場規模は？
→DataM Intelligence社は2023年のセチリジン塩酸塩の世界市場規模を67億9790万米ドルと推定しています。

・セチリジン塩酸塩の世界市場予測は？
→DataM Intelligence社は2031年のセチリジン塩酸塩の世界市場規模を88億8250万米ドルと予測しています。

・セチリジン塩酸塩市場の成長率は？
→DataM Intelligence社はセチリジン塩酸塩の世界市場が2024年～2031年に年平均3.4%成長すると展望しています。

・世界のセチリジン塩酸塩市場における主要プレイヤーは？
→「Johnson & Johnson Services, Inc.、GSK plc、UCB S.A.、Teva Pharmaceutical Industries Ltd.、Pfizer Inc.、Major Pharmaceuticals、Cipla、Dr. Reddys Laboratories Ltd.、AdvaCare Pharma、Aden Healthcareなど ...」をセチリジン塩酸塩市場のグローバル主要プレイヤーとして判断しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/